Amgen (AMGN) Common Equity (2009 - 2026)

Amgen has reported Common Equity for 18 years, with the latest figure at $11.7 billion in Q2 2026.

• On a quarterly basis, Common Equity rose 57.35% year-over-year to $11.7 billion in Q2 2026; TTM through Jun 2026 was $11.7 billion, a 57.35% increase from a year earlier, with the FY2025 full-year figure at $8.7 billion, up 47.32% from the prior year.
• Common Equity was $11.7 billion for Q2 2026 at Amgen, up from $9.2 billion in the prior quarter.
• The five-year high for Common Equity was $11.7 billion in Q2 2026, with the low at $916.0 million in Q1 2022.
• Average Common Equity over 5 years is $6.3 billion, with a median of $6.2 billion recorded in 2023.
• The sharpest annual moves came in 2022 and 2023: Common Equity sank 90.19% in 2022, then jumped 483.84% in 2023.
• Over 5 years, Common Equity stood at $3.7 billion in 2022, then jumped by 70.23% to $6.2 billion in 2023, then slipped by 5.7% to $5.9 billion in 2024, then jumped by 47.32% to $8.7 billion in 2025, then jumped by 35.0% to $11.7 billion in 2026.
• The last three Common Equity figures came in at $11.7 billion (Q2 2026), $9.2 billion (Q1 2026), and $8.7 billion (Q4 2025), per Business Quant data.